Carisma Therapeutics
CARM
CARM was delisted on the 10th of October, 2025.
41 hedge funds and large institutions have $40M invested in Carisma Therapeutics in 2015 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 15 increasing their positions, 7 reducing their positions, and 24 closing their positions.
114% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 7
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
20% less funds holding
Funds holding: 51 → 41 (-10)
42% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 24
66% less capital invested
Capital invested by funds: $119M → $40M (-$79.1M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$7.85M |
| 2 |
RG
Redmile Group
San Francisco,
California
|
+$7.21M |
| 3 |
Franklin Resources
San Mateo,
California
|
+$5.57M |
| 4 |
O
OrbiMed
New York
|
+$5.16M |
| 5 |
BA
BlackRock Advisors
Wilmington,
Delaware
|
+$612K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Broadfin Capital
New York
|
-$8.62M |
| 2 |
RA
Royce & Associates
New York
|
-$3.47M |
| 3 |
JP Morgan Chase
New York
|
-$2.66M |
| 4 |
AC
Ascend Capital
Orinda,
California
|
-$1.87M |
| 5 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
-$1.75M |
CARM Hedge Fund Activity: Q2 2015 in Review
41 of the 3,712 institutional investors tracked by Wall St. Rank reported a position in Carisma Therapeutics (CARM) for Q2 2015, worth a combined $40M — down 66% from $119M a quarter earlier.
Sellers outnumbered buyers: 24 funds closed out of CARM and 14 opened new positions — a net loss of 10 holders — while 7 trimmed existing stakes and 15 added.
The largest buyer was Fidelity Investments, adding an estimated $7.85M. The largest seller was Broadfin Capital, exiting entirely with an estimated $8.62M sold.
- 41 institutional investors held Carisma Therapeutics (CARM) as of Q2 2015, down from 51 in Q1 2015.
- Funds reported $40M of Carisma Therapeutics stock for Q2 2015, down 66% quarter-over-quarter.
- 14 funds opened new Carisma Therapeutics positions in Q2 2015 and 24 closed out, a net change of -10 holders.
- The largest Carisma Therapeutics buyer in Q2 2015 was Fidelity Investments, an estimated $7.85M added.
- The largest Carisma Therapeutics seller in Q2 2015 was Broadfin Capital, an estimated $8.62M sold.
Based on aggregated 13F filings for Q2 2015.